Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11930.0
(-0.33%)
KRW 11930.0
(-0.33%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 98.12 Billion KRW | -0.68% |
| 2022 | 98.79 Billion KRW | 5.67% |
| 2021 | 93.49 Billion KRW | 7.96% |
| 2020 | 86.6 Billion KRW | 9.37% |
| 2019 | 79.18 Billion KRW | -0.15% |
| 2018 | 79.3 Billion KRW | 0.58% |
| 2017 | 78.84 Billion KRW | 13.74% |
| 2016 | 69.31 Billion KRW | -4.49% |
| 2015 | 72.57 Billion KRW | 10.22% |
| 2014 | 65.85 Billion KRW | 14.25% |
| 2013 | 57.63 Billion KRW | 6.98% |
| 2012 | 53.87 Billion KRW | -4.08% |
| 2011 | 56.17 Billion KRW | 1.71% |
| 2010 | 55.22 Billion KRW | 6.02% |
| 2009 | 52.09 Billion KRW | 5.56% |
| 2008 | 49.34 Billion KRW | 7.79% |
| 2007 | 45.77 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 68.11 Billion KRW | -5.83% |
| 2024 Q2 | 24.41 Billion KRW | -0.25% |
| 2024 Q1 | 24.47 Billion KRW | 3.93% |
| 2023 FY | 98.12 Billion KRW | -0.68% |
| 2023 Q1 | 23.92 Billion KRW | 1.4% |
| 2023 Q4 | 23.55 Billion KRW | -8.1% |
| 2023 Q3 | 25.62 Billion KRW | -0.66% |
| 2023 Q2 | 25.79 Billion KRW | 7.85% |
| 2022 Q2 | 24.47 Billion KRW | -2.57% |
| 2022 Q1 | 25.11 Billion KRW | 12.15% |
| 2022 Q4 | 23.59 Billion KRW | -7.9% |
| 2022 Q3 | 25.61 Billion KRW | 4.67% |
| 2022 FY | 98.79 Billion KRW | 5.67% |
| 2021 Q3 | 22.79 Billion KRW | 2.62% |
| 2021 FY | 93.49 Billion KRW | 7.96% |
| 2021 Q1 | 26.08 Billion KRW | 12.69% |
| 2021 Q2 | 22.21 Billion KRW | -14.84% |
| 2021 Q4 | 22.39 Billion KRW | -1.75% |
| 2020 Q3 | 21.96 Billion KRW | 10.32% |
| 2020 Q2 | 19.9 Billion KRW | -7.77% |
| 2020 FY | 86.6 Billion KRW | 9.37% |
| 2020 Q1 | 21.58 Billion KRW | 20.91% |
| 2020 Q4 | 23.14 Billion KRW | 5.4% |
| 2019 Q4 | 17.85 Billion KRW | -9.19% |
| 2019 Q2 | 20.25 Billion KRW | -5.43% |
| 2019 Q1 | 21.41 Billion KRW | 15.33% |
| 2019 FY | 79.18 Billion KRW | -0.15% |
| 2019 Q3 | 19.65 Billion KRW | -2.94% |
| 2018 Q1 | 19.45 Billion KRW | 0.8% |
| 2018 FY | 79.3 Billion KRW | 0.58% |
| 2018 Q4 | 18.57 Billion KRW | -7.71% |
| 2018 Q3 | 20.12 Billion KRW | -4.88% |
| 2018 Q2 | 21.15 Billion KRW | 8.75% |
| 2017 Q4 | 19.29 Billion KRW | 1.9% |
| 2017 FY | 78.84 Billion KRW | 13.74% |
| 2017 Q2 | 20.01 Billion KRW | -2.83% |
| 2017 Q1 | 20.59 Billion KRW | 28.6% |
| 2017 Q3 | 18.93 Billion KRW | -5.38% |
| 2016 Q4 | 16.01 Billion KRW | -12.51% |
| 2016 Q3 | 18.3 Billion KRW | -0.94% |
| 2016 Q2 | 18.48 Billion KRW | 11.89% |
| 2016 Q1 | 16.51 Billion KRW | -7.5% |
| 2016 FY | 69.31 Billion KRW | -4.49% |
| 2015 Q4 | 17.85 Billion KRW | -6.34% |
| 2015 FY | 72.57 Billion KRW | 10.22% |
| 2015 Q2 | 18.81 Billion KRW | 11.74% |
| 2015 Q3 | 19.06 Billion KRW | 1.31% |
| 2015 Q1 | 16.84 Billion KRW | -1.66% |
| 2014 Q3 | 16.54 Billion KRW | -0.14% |
| 2014 FY | 65.85 Billion KRW | 14.25% |
| 2014 Q4 | 17.12 Billion KRW | 3.49% |
| 2014 Q2 | 16.57 Billion KRW | 6.18% |
| 2014 Q1 | 15.6 Billion KRW | 2.14% |
| 2013 Q2 | 14.91 Billion KRW | 12.5% |
| 2013 Q1 | 13.25 Billion KRW | -7.33% |
| 2013 FY | 57.63 Billion KRW | 6.98% |
| 2013 Q4 | 15.27 Billion KRW | 7.69% |
| 2013 Q3 | 14.18 Billion KRW | -4.86% |
| 2012 Q1 | 12.05 Billion KRW | -11.01% |
| 2012 Q2 | 13.53 Billion KRW | 12.28% |
| 2012 Q3 | 13.97 Billion KRW | 3.23% |
| 2012 FY | 53.87 Billion KRW | -4.08% |
| 2012 Q4 | 14.3 Billion KRW | 2.36% |
| 2011 FY | 56.17 Billion KRW | 1.71% |
| 2011 Q2 | 14.12 Billion KRW | -1.1% |
| 2011 Q4 | 13.54 Billion KRW | -4.65% |
| 2011 Q1 | 14.28 Billion KRW | -0.69% |
| 2011 Q3 | 14.2 Billion KRW | 0.57% |
| 2010 Q2 | 13.41 Billion KRW | -1.08% |
| 2010 FY | 55.22 Billion KRW | 6.02% |
| 2010 Q4 | 14.38 Billion KRW | 3.8% |
| 2010 Q3 | 13.85 Billion KRW | 3.29% |
| 2010 Q1 | 13.56 Billion KRW | 6.55% |
| 2009 Q1 | 13.6 Billion KRW | 10.25% |
| 2009 FY | 52.09 Billion KRW | 5.56% |
| 2009 Q3 | 13.29 Billion KRW | 6.67% |
| 2009 Q2 | 12.46 Billion KRW | -8.41% |
| 2009 Q4 | 12.73 Billion KRW | -4.23% |
| 2008 FY | 49.34 Billion KRW | 7.79% |
| 2008 Q1 | 13.12 Billion KRW | 12.4% |
| 2008 Q2 | 11.55 Billion KRW | -11.98% |
| 2008 Q3 | 12.32 Billion KRW | 6.63% |
| 2008 Q4 | 12.34 Billion KRW | 0.16% |
| 2007 Q4 | 11.67 Billion KRW | -2.29% |
| 2007 Q1 | 10.75 Billion KRW | 0.0% |
| 2007 Q2 | 11.39 Billion KRW | 6.0% |
| 2007 FY | 45.77 Billion KRW | 0.0% |
| 2007 Q3 | 11.95 Billion KRW | 4.89% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -110.999% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 73.051% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 50.663% |
| HANDOK Inc. | 151.36 Billion KRW | 35.174% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -45.967% |
| Yuhan Corporation | 564.5 Billion KRW | 82.618% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 69.546% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -313.211% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 88.26% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -30.765% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 50.681% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -141.393% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -3.819% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 30.336% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -110.999% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -182.654% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -27.737% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 914.615% |
| JW Holdings Corporation | 446.15 Billion KRW | 78.007% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 52.72% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 85.027% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 70.767% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -24.81% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -30.42% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -35.886% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 46.617% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -110.999% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 66.751% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 85.603% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 70.767% |
| Yuhan Corporation | 564.5 Billion KRW | 82.618% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 51.38% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -38.323% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 0.911% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 70.767% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 32.741% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 43.44% |
| CKD Bio Corp. | 5.01 Billion KRW | -1858.473% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 61.403% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 46.707% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -24.81% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 73.587% |
| Boryung Corporation | 333.26 Billion KRW | 70.557% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -96.072% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 50.681% |
| JW Lifescience Corporation | 51.32 Billion KRW | -91.185% |